Patrick Vizeli
Postdoctoral Researcher in Clinical Pharmacology
Data updated
Research Footprint
Patrick Vizeli appears in 26 tracked papers (2017–2026), most studied alongside MDMA, LSD and Placebo, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Anxiety Disorders.
Most-cited paper: Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. (248 citations).
Frequent co-authors: Matthias Liechti, Friederike Holze and Lukas Ley.
Background & Research
Patrick Vizeli is a researcher at the University of California San Diego and the University of Basel. His work focuses on the human pharmacology of classic psychedelics, specifically LSD. He investigates how personality traits, mood, and genetic variations impact the subjective and physiological effects of these substances, aiming to refine their therapeutic application for psychiatric and neurological disorders.
Key Impact
Investigates the pharmacogenetics and non-pharmacological factors influencing LSD response.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Patrick Vizeli is associated with.
University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →University of California San Diego
academicThe Psychedelics and Health Research Initiative (PHRI) focuses heavily on conducting pilot studies and clinical trials while collecting diverse biometric data—including fMRI, EEG, and cognitive metrics—from study participants. This data-driven approach aims to unravel the biological and neurological underpinnings of how psychedelics facilitate healing.
View stakeholder →